Breast Cancer

The ANTHEM Feasibility Study, Is A Novel THErapeutic mammaplasty procedure a safe and effective alternative to Mastectomy for treatment of breast cancer?

A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for her2-positive breast cancer at high risk of recurrence following preoperative therapy

Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases
at presentation after neoadjuvant chemotherapy

Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women

IMproving PAtient undeRstanding of GEP TEst Results: Phase 4

A Randomised, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer

National study of management of breast cancer locoregional recurrence and oncologic outcome

National study of management of breast cancer locoregional recurrence and oncological outcome

Multicenter, multi-country, prospective, observational, post authorisation safety study to describe the incidence of discontinuation due to diarrhoea within the first 3 months of treatment with neratinib, in adult breast cancer patients treated in extended adjuvant in a real world setting: the NERLYFE study. Ancillary study: A Nerlyfe ancillary study to describe recurrence in breast cancer patients treated with neratinib in a real-world setting

A prospective, non-randomised, multi-centre feasibility study to assess if patients residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis

A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer

Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib

Exploring the experiences and outcomes of patients not offered immediate breast REconstruction after maSTectOmy for bREast cancer during the COVID-19 pandemic

Response To Optimal Selection Of Neo-Adjuvant Chemotherapy In Operable Breast Cancer

A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)